BCL2L12
Bcl-2-like protein 12
Also known as: B2L12_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9HB09
- Gene
- BCL2L12
- Ensembl
- ENSG00000126453
- Chromosome
- 19
- Canonical length
- 250 aa
- Protein class
- Predicted intracellular proteins
- Subcellular location
- Vesicles,Plasma membrane
OverviewNCBI Gene
This gene encodes a member of a family of proteins containing a Bcl-2 homology domain 2 (BH2). The encoded protein is an anti-apoptotic factor that acts as an inhibitor of caspases 3 and 7 in the cytoplasm. In the nucleus, it binds to the p53 tumor suppressor protein, preventing its association with target genes. Overexpression of this gene has been detected in a number of different cancers. There is a pseudogene for this gene on chromosome 3. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Sep 2013]
Canonical amino-acid sequenceUniProt
250 residues, UniProt reviewed canonical sequence.
>Q9HB09|BCL2L12
1 MAGSEELGLR EDTLRVLAAF LRRGEAAGSP VPTPPRSPAQ EEPTDFLSRL RRCLPCSLGR
61 GAAPSESPRP CSLPIRPCYG LEPGPATPDF YALVAQRLEQ LVQEQLKSPP SPELQGPPST
121 EKEAILRRLV ALLEEEAEVI NQKLASDPAL RSKLVRLSSD SFARLVELFC SRDDSSRPSR
181 ACPGPPPPSP EPLARLALAM ELSRRVAGLG GTLAGLSVEH VHSFTPWIQA HGGWEGILAV
241 SPVDLNLPLDLocalizationUniProt · AlphaFold · HPA
Whether an antibody against BCL2L12 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.48
- Highest tissue expression
- 19 nTPM
Expression across tissuesHPA
Tissue
- lymph node: 19 nTPM
- bone marrow: 17 nTPM
- thymus: 16 nTPM
- spleen: 15 nTPM
- tonsil: 15 nTPM
- liver: 14 nTPM
Single-cell type
- extravillous trophoblasts: 154 nCPM
- epicardial cells: 102 nCPM
- migrating cytotrophoblasts: 96 nCPM
- cytotrophoblasts: 85 nCPM
- cardiomyocytes: 67 nCPM
- esophageal basal cells: 61 nCPM
Immune cell
- plasmacytoid DC: 26 nTPM
- eosinophil: 17 nTPM
- NK-cell: 16 nTPM
- memory B-cell: 15 nTPM
- naive B-cell: 15 nTPM
- MAIT T-cell: 15 nTPM
Brain region
- choroid plexus: 5.4 nTPM
- medulla oblongata: 4.3 nTPM
- white matter: 4 nTPM
- midbrain: 3.6 nTPM
- thalamus: 3.5 nTPM
- spinal cord: 3.4 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.38
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.14
- DepMap mean gene effect
- -0.2
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 7% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- apoptotic process
- negative regulation of apoptotic process
- negative regulation of cellular senescence
- negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator
- positive regulation of transcription by RNA polymerase II
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of BCL2L12 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads BCL2L12 as an antibody target. Whether an autoantibody or antibody against BCL2L12 could matter depends on whether native BCL2L12 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
BCL2L12 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label BCL2L12 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...